Advertisement

Search Results

Advertisement



Your search for ASCO matches 21353 pages

Showing 19401 - 19450


New Symposium Brings Together Oncologists and Primary Care Providers to Advance Survivorship Care and Research

With two-thirds of Americans now living at least 5 years after a cancer diagnosis, there are currently 14.5 million cancer survivors living in the United States. By 2024, that number is expected to increase by nearly 25%.1 Although the growing number of survivors is a welcome sign of progress, this ...

15th Annual Conference of the International Society of Geriatric Oncology (SIOG)

Join the best minds in Geriatric Oncology during the 15th SIOG Annual Conference taking place in Prague, Czech Republic, on November 12–14, 2015. The 3-day scientific program of SIOG 2015 will have the theme: “Geriatric Oncology and Supportive Care: A Global Approach to Advance the Science.”   ...

bladder cancer
prostate cancer
gynecologic cancers

Clinical Trials Actively Recruiting Patients With Genitourinary Cancers

The information contained in this Clinical Trials Resource Guide includes actively recruiting clinical studies for patients with genitourinary cancers—prostate, bladder, uterine, and testicular. The trials are investigating genetic biomarkers of cancer; proton beam therapy; allogeneic bone marrow...

APOS Announces 2015 Award Winners at the World Congress of Psycho-Oncology

The American Psychosocial Oncology Society (APOS) honored five award winners at the 2015 World Congress of Psycho-Oncology, held from July 28–August 1 in Washington, DC. Holland Distinguished Leadership Award: Matthew J. Loscalzo, LCSW  Professor Loscalzo is the Liliane Elkins Professor in...

Penn’s Basser Center for BRCA Names David Livingston, MD, Winner of 2015 Annual Basser Global Prize

The Basser Center for BRCA at Penn’s Abramson Cancer Center has announced the recipient of its third annual Basser Global Prize: molecular cancer expert David ­Livingston, MD, Emil Frei Professor of Genetics and Medicine at Harvard Medical School and Deputy Director of the Dana-Farber/Harvard...

cns cancers

Improved Understanding of Glioma Tumor Biology

The management of patients with lower-grade gliomas is evolving. As evidenced by two recent publications in The New England Journal of Medicine,1,2 reviewed in this issue of The ASCO Post, there has been a substantial increase in our knowledge of the molecular characteristics of these neoplasms....

breast cancer

The Conundrum of Estrogen-Receptor Signaling in HER2-Positive Breast Cancer

BOLERO-1—reviewed in this issue of The ASCO Post—is the next installment in a series of randomized trials evaluating the addition of everolimus (Afinitor) to standard therapy in metastatic breast cancer.1 The initial evaluation of everolimus in the HER2-positive metastatic setting looked extremely...

cost of care

Calculating the Value of Cancer Drugs

For nearly a decade, Peter B. Bach, MD, MAPP, Director of the Center for Health Policy and Outcomes at Memorial Sloan Kettering Cancer Center in New York, has been a leading voice in sounding the alarm over the escalating cost of cancer drugs and in seeking a solution to the problem. In 2012, Dr....

Children’s Hospital of Philadelphia Appoints Madeline Bell, MS, as CEO

The Children’s Hospital of Philadelphia (CHOP) announced that Madeline Bell, MS, formerly President and Chief Operating Officer, has been appointed President and Chief Executive Officer and will succeed Steven M. Altschuler, MD, as CEO. The transition of leadership was completed on July 1, 2015....

colorectal cancer

Learning to Refine the Use of Regorafenib to Best Advantage in Advanced Colorectal Cancer

In patients with advanced colorectal cancer who have been heavily treated with a sequence of chemotherapy regimens and/or targeted therapies, the goals of treatment on or off a clinical trial are readily definable. These patients and their managing teams are striving to extend the length of lives,...

skin cancer

FDA Approves Sonidegib for Locally Advanced Basal Cell Carcinoma

The U.S. Food and Drug Administration (FDA) approved sonidegib (Odomzo) for the treatment of patients with locally advanced basal cell carcinoma that has recurred following surgery or radiation therapy or those who are not candidates for surgery or radiation therapy. The approval was based on...

sarcoma

Dactinomycin Formulation Gets Orphan Drug Designation

The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to NanoSmart Pharmaceuticals’ novel formulation of dactinomycin for the treatment of Ewing sarcoma, a rare type of childhood bone cancer. The designation was granted on the basis of a plausible hypothesis that the novel ...

kidney cancer

FDA Grants Breakthrough Therapy Designation to Lenvatinib for Metastatic Renal Cell Carcinoma

The U.S. Food and Drug Administration (FDA) granted lenvatinib (Lenvima) Breakthrough Therapy designation for investigational use in patients with advanced or metastatic renal cell carcinoma who were previously treated with a vascular endothelial growth factor (VEGF)-targeted therapy. Lenvatinib...

multiple myeloma

FDA Approves Carfilzomib Combination for Patients With Relapsed Multiple Myeloma

The U.S. Food and Drug Administration (FDA) approved carfilzomib (Kyprolis) in combination with lenalidomide (Revlimid) and dexamethasone for the treatment of patients with relapsed multiple myeloma who have received one to three prior lines of therapy. In the United States, there are nearly...

lung cancer

Immunotherapy Makes Inroads in Small Cell Lung Cancer

Early data on immunotherapy for small cell lung cancer (SCLC) have been encouraging. SCLC may catch up to non–small cell lung cancer (NSCLC), where immunotherapy is now standard of care, if these early data are borne out in phase III trials. Phase Ib and II studies of immunotherapy in SCLC were...

lung cancer

Moving Forward in Non–Small Cell Lung Cancer: Targeted Combinations and Immunotherapy

The newer targeted therapies and immunotherapies have proven to be a boon to the treatment of lung and other cancers, but how best to deploy those therapies remains a burning question. Another important focus of current research is the identification and validation of biomarkers for these...

lung cancer

Immune Checkpoint Inhibitors: The Dawn of a New Era for Lung Cancer Therapy

The therapeutic paradigm for lung cancer has changed rapidly over the past few years toward individualized therapy. For certain subsets of patients, molecularly targeted agents have resulted in robust gains in overall survival and quality of life. However, for the majority of patients with...

breast cancer

Studies Explore New Avenues to Pursue in Metastatic Triple-Negative Breast Cancer

Two agents targeting novel pathways show promise in metastatic triple-negative breast cancer, according to separate studies presented at the 2015 ASCO Annual Meeting and reviewed at the Best of ASCO® meeting by Steven J. Isakoff, MD, PhD, of Massachusetts General Hospital, Boston. The first study...

James Welsh, MD, FACRO, Elected President of the American College of Radiation Oncology

Loyola University Medical Center radiation oncologist James Welsh, MD, FACRO, was recently elected president of the American College of Radiation Oncology (ACRO). Dr. Welsh, installed as president during ACRO’s Annual Meeting in Washington, DC, will serve a 2-year term as President. In 2017, Dr....

Joxel Garcia, MD, to Direct MD Anderson Moon Shots Program Prevention Efforts

The University of Texas MD Anderson Cancer Center has appointed former United States Public Health Service four-star Admiral Joxel Garcia, MD, as the inaugural Executive Director of the Cancer Prevention and Control Platform, part of MD Anderson’s Moon Shots Program. He joined MD Anderson on August ...

Expect Questions or Ask About Postmastectomy Pain

Since postmastectomy pain occurs in an estimated 20% to 40% of patients undergoing the procedure, physicians who treat these women can expect questions about the pain and how to deal with it. However, some patients may be reluctant to ask about it. “Sometimes, women don’t want to complain to their ...

breast cancer
pain management

Increased Interest in Simple Injection to Treat Women With Postmastectomy Pain

After presenting results of a study showing that injecting a standard analgesic combination into trigger points of pain along the inframammary fold relieved postmastectomy pain, Laura J. Esserman, MD, MBA, Director of the Carol Franc Buck Breast Care Center and Co-Leader of the Breast Oncology...

survivorship

Mayo Clinic Receives $11 Million Grant from NCI to Study NHL Survivorship

Mayo Clinic has received a 5-year, $11 million grant from the National Cancer Institute (NCI) to study survivorship in patients with non-Hodgkin lymphoma (NHL). The Lymphoma Epidemiology of Outcomes Cohort Study will enroll 12,000 patients with NHL. The study will follow these patients for...

Unneccessary Complexity in Scientific Terminology?

In the highlighted quote in the article titled “Ado-Trastuzumab Emtansine Fails to Replace Standard of Care in First-Line Metastatic Breast Cancer,” which appeared in on page 3 of the July 10 issue of The ASCO Post, a most remarkable sentence was constructed: T-DM1 and T-DM1 plus pertuzumab...

2015 Oncology Meetings

SEPTEMBER 2015 Breast Cancer SymposiumSeptember 25-27 • San Francisco, California For more information: breastcasym.org The European Cancer CongressSeptember 25-29 • Vienna, Austria For more information: www.esmo.org/Conferences/European-Cancer-Congress-2015 17th Annual International Meeting of...

ASCO and UICC Collaborate to Extend Reach of the Journal of Global Oncology

ASCO and the Union for International Cancer Control (UICC) announced their partnership to expand the reach of the Journal of Global Oncology (JGO), a new open-access journal that will focus on cancer care, research, and care delivery issues unique to countries and settings with limited health-care...

From Small-Town Mexico to Big Pharma, a Look at Opiates for Good and Bad

Bookmark Title: Dreamland: The True Tale of America’s Opiate Epidemic Author: Sam Quinones Publisher: Bloomsbury Press Publication date:  April 21, 2015 Price: $28.00; hardcover, 384 pages Despite growing awareness within the oncology community and the emergence of the palliative care...

Chris Marshall, FRS, FMedSci, Dies at 66 of Colorectal Cancer

Chris Marshall, FRS, FMedSci, a rigorous scientist with a lasting legacy of game-changing discoveries in cancer research and generous support for his younger colleagues, has died at 66. The cause of death was colorectal cancer. Professor Marshall was the Head of the Division for Cancer Biology at...

Breast Surgeon Carolyn Mary Kaelin, MD, MPH, FACS, Dies at 54

Carolyn Mary Kaelin, MD, MPH, FACS, died on July 28 at the age of 54. A gifted and compassionate breast cancer surgeon, Dr. Kaelin was a surgical oncologist in the Women’s Cancers Program at Dana-Farber Cancer Center and Director of the Breast Clinic at Brigham and Women’s Hospital. Dr. Kaelin...

integrative oncology

Coriolus versicolor

The use of dietary supplements by patients with cancer has increased significantly over the past 20 years despite insufficient evidence of safety and effectiveness. Finding reliable sources of information about dietary supplements can be daunting. Patients typically rely on family, friends, and the ...

Diane Simeone, MD, Named Upcoming Chair of PanCAN Scientific Board

Diane Simeone, MD, Director of the Pancreatic Cancer Center at the University of Michigan, was recently named the Upcoming Chair of the National Scientific and Medical Advisory Board for the Pancreatic Cancer Action Network (PanCAN). Her 2-year term as Chair runs from 2017 to 2019. Dr. Simeone will ...

Thomas J. Lynch Jr, MD, Leaves Yale Cancer Center

Thomas J. Lynch Jr, MD, Director of Yale Cancer Center and Physician-in-Chief of Smilow Cancer Hospital at Yale-New Haven, left Yale in August to become Chairman and Chief Executive Officer of the Massachusetts General Physicians Organization. Dr. Lynch joined Yale Cancer Center as Director in 2009 ...

A Cancer Handbook for Inquisitive Laypersons and Health-Care Professionals

Bookmark Title: The Cancer Solution: Taking Charge of Your Life With CancerAuthor: Jack C. Westman, MD, MSPublisher: Archway PublishingPublication date:  January 15, 2015Price: $20.00; paperback, 310 pages I was at a meeting in San Francisco in 1978 and received a call from my wife, Nancy:...

Hypertrophic Tumor of the Forehead, Philadelphia, Circa 1870

Through the Lens of Oncology History: A Century of Progress The text and photographs on this page are excerpted from a four-volume series of books titled Oncology Tumors & Treatment: A Photographic History, by Stanley B. Burns, MD, FACS. The photos below are from the volume titled “The...

Andrew S. Chi, MD, PhD, Named Head of Neuro-Oncology at NYU’s  Laura and Isaac Perlmutter Cancer Center

New York University (NYU) Langone Medical Center announced the appointment of physician-scientist and brain tumor specialist Andrew S. Chi, MD, PhD, as Chief of Neuro-Oncology for its Laura and Isaac Perlmutter Cancer Center and Co-Director of the NYU Langone Brain Tumor Center. In his new role,...

Iuliana Shapira, MD, Named Chief of Hematology and Oncology at SUNY Downstate

Iuliana Shapira, MD, has joined SUNY Downstate Medical Center as Chief of the Division of Hematology and Oncology. In this position, Dr. Shapira will provide leadership in the clinical, academic, and administrative aspects of the program, as well as broaden the relationship with SUNY Downstate’s...

Jeffrey Rathmell, PhD, to Lead New Center for Immunobiology at Vanderbilt

Jeffrey Rathmell, PhD, has been recruited to Vanderbilt University Medical Center (VUMC) to lead a new Center for Immunobiology, a structure supported by the Department of Pathology, Microbiology, and Immunology, the Department of Medicine, and Vanderbilt-Ingram Cancer Center (VICC). He took on his ...

W. Kimryn Rathmell, MD, PhD, Will Direct Division of Hematology and Oncology at Vanderbilt

W. Kimryn Rathmell, MD, PhD, Alexander Professor for Translational Science and Associate Director for Training and Education at the University of North Carolina’s Lineberger Comprehensive Cancer Center, has been named Director of Vanderbilt’s Division of Hematology and Oncology. She began her new...

The Flipped Classroom: Swapping the Traditional Lecture Hall for an Online Version

Despite enormous advances in modern medicine and the explosion of biomedical information over the past century, the way medical education is taught in the United States is stuck in a format that does not optimize learning, according to Charles Prober, MD, Senior Associate Dean for Medical Education ...

issues in oncology

Access to Cancer Medicines Not Uniform Across Europe

Access to cancer medicines—including some old standbys—is inconsistent across Europe, depriving many patients of treatments that are the standard of care elsewhere,1 according to Alexandru E. Eniu, MD, PhD, Chair of the European Society for Medical Oncology (ESMO) Emerging Countries Committee and...

Massimo Cristofanilli, MD, Named Associate Director for Precision Medicine and Translational Research at Lurie Cancer Center

Breast cancer expert Massimo ­Cristofanilli, MD, has been appointed Associate Director for Precision Medicine and Translational Research at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and Director of Northwestern Onco-SET (Sequence, Evaluate, Treat). Dr. Cristofanilli ...

Seventeen ASTRO Members Awarded Fellows Designation

The American Society for Radiation Oncology (ASTRO) has selected 17 distinguished members to receive the ASTRO Fellows designation. The 2015 class of Fellows will receive the recognition at the Awards Ceremony at ­ASTRO’s 57th Annual Meeting on Tuesday, October 20 in San Antonio, Texas. ASTRO...

skin cancer

COMBI-d Trial and the Need to Guide Progress in Melanoma Treatment

As reviewed in this issue of The ASCO Post, Long et al1 have reported the final overall survival analysis of the COMBI-d phase III trial comparing combination therapy with the BRAF inhibitor dabrafenib (Tafinlar) and the MEK inhibitor trametinib (Mekinist) to monotherapy with dabrafenib alone,...

Join Us for the Community Research Forum Annual Meeting

This year’s Community Research Forum Annual Meeting is right around the corner. There is an exciting lineup scheduled for the meeting, with participants and presenters representing a range of practices and types of research programs. Participants will engage with one another in breakout sessions to ...

This September, Triple Your Impact

At the 2015 ASCO Annual Meeting, the Conquer Cancer Foundation (CCF) launched The Campaign to Conquer Cancer—a comprehensive, $150 million fundraising campaign supporting breakthrough research and sharing vital knowledge with physicians, patients, and families. In support of The Campaign, CCF Board ...

Conquer Cancer Foundation Young Investigator Award Applications Now Open

The Conquer Cancer Foundation’s Young Investigator Award (YIA) provides research funding to promising physicians to support the transition from final years of training to faculty appointment and to encourage and promote quality research in clinical oncology. The online application for 2016 YIAs is...

issues in oncology

Journal of Clinical Oncology Special Series Issues Provide Updates on Important Topics in Oncology Practice

Journal of Clinical Oncology (JCO) annually publishes several Special Series of reviews—disease-specific issues dedicated to providing readers with concise, authoritative updates on important topics in oncology practice. Each issue of the Special Series explores one specific area of cancer care...

Order ASCO Answers Guides to Cancer for Your Practice

ASCO Answers Guides to breast, colorectal, lung, and prostate cancers are designed to help newly diagnosed patients understand their disease and treatment options. These comprehensive, patient-friendly booklets contain trusted information about the diagnosis, treatment, side effects, and...

ASCO Guidelines: A Collaborative Effort

The ASCO Guidelines Program has worked with other professional societies and guideline development organizations in an effort to expand the ASCO guideline portfolio and harmonize recommended care options across prominent guideline development groups. For ASCO, this effort began with a systematic...

St. Jude Names Keith Perry, MBA, as Chief Information Officer

St. Jude Children’s Research Hospital has named Keith Perry, MBA, as Chief Information Officer (CIO) to provide strategic counsel and leadership for the hospital’s information technology initiatives.   “Our internal information technology systems and operations play a critical role in the success...

Advertisement

Advertisement




Advertisement